Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Accumulated Expenses (2021 - 2025)

Roivant Sciences' Accumulated Expenses history spans 5 years, with the latest figure at $118.0 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 200.4% year-over-year to $118.0 million; the TTM value through Dec 2025 reached $118.0 million, up 200.4%, while the annual FY2025 figure was $114.3 million, 4.29% down from the prior year.
  • Accumulated Expenses reached $118.0 million in Q4 2025 per ROIV's latest filing, up from $108.3 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $167.1 million in Q1 2023 to a low of $19.9 million in Q2 2023.
  • Average Accumulated Expenses over 5 years is $88.1 million, with a median of $106.2 million recorded in 2021.
  • Peak YoY movement for Accumulated Expenses: crashed 81.78% in 2023, then surged 594.11% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $112.7 million in 2021, then tumbled by 62.8% to $41.9 million in 2022, then soared by 83.46% to $76.9 million in 2023, then crashed by 48.92% to $39.3 million in 2024, then skyrocketed by 200.4% to $118.0 million in 2025.
  • Per Business Quant, the three most recent readings for ROIV's Accumulated Expenses are $118.0 million (Q4 2025), $108.3 million (Q3 2025), and $26.5 million (Q2 2025).